newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

Bengaluru, June 12, 2024: Glenmark Specialty SA (Glenmark) has received final approval from the United States Food & Drug Administration (U.S. FDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC), determined by the FDA to be bioequivalent1 to Nexium®2 24 HR Delayed-Release Capsules, 20 mg (OTC), of Haleon U.S. Holdings LLC. Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

According to Nielsen® syndicated data for the latest 52-week period ending May 18, 2024, the Nexium® 24 HR Delayed-Release Capsules, 20 mg (OTC) market3 achieved annual sales of approximately $259.2 million*.

Glenmark’s current portfolio consists of 197 products authorized for distribution in the U.S. marketplace and 50 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Related posts

Torque Pharma Introduces its Newest Product under “Torque Kvach Anti Lice Cream Wash”

Newsmantra

Three Tips You Should Know for Breast Cancer Awareness Month

Newsmantra

मुजफ्फरपुर के होमी भाभा कैंसर अस्पताल एवं अनुसंधान केंद्र में मुख्यमंत्री ने किया ऑपरेशन थियेटर का उद्घाटन

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More